Zymeworks (ZYME) Posts Revs of $1.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Zymeworks Reports Second Quarter 2017 Financial Results
August 8, 2017 4:01 PM EDTVANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Zymeworks) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the second quarter ended June 30, 2017.
During the second quarter, in addition to the completion of our initial public offering, we made significant progress on our clinical and partnered programs, said Ali Tehrani, Ph.D., Zymeworks President & CEO. We presented detailed dose escalation data at ASCO demonstrating safety and anti-tumor activity for ZW25. We also announced progress... More
